Trial Profile
Switching to sirolimus versus continuing an mTOR inhibitor for the prevention of rejection in renal transplant recipients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Jan 2013
Price :
$35
*
At a glance
- Drugs Sirolimus (Primary) ; Azathioprine; Ciclosporin; Immunosuppressants; Mycophenolate mofetil; Prednisone; Tacrolimus
- Indications Renal transplant rejection
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 05 Nov 2010 New trial record.